torcetrapib has been researched along with avasimibe in 1 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (avasimibe) | Trials (avasimibe) | Recent Studies (post-2010) (avasimibe) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 77 | 6 | 30 |
| Protein | Taxonomy | torcetrapib (IC50) | avasimibe (IC50) |
|---|---|---|---|
| Sterol O-acyltransferase 1 | Rattus norvegicus (Norway rat) | 0.5345 | |
| Sterol O-acyltransferase 2 | Homo sapiens (human) | 9.2 | |
| Sterol O-acyltransferase 1 | Homo sapiens (human) | 1.526 | |
| Sterol O-acyltransferase 1 | Mus musculus (house mouse) | 0.47 | |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | 7.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdallah, M; Abi Rafeh, N; Bhat, T; El-Sayegh, S; Kalantar-Zadeh, K; Khoueiry, G; Lafferty, J; Raza, M; Saiful, F | 1 |
1 review(s) available for torcetrapib and avasimibe
| Article | Year |
|---|---|
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Niacin; PPAR alpha; Quinolines; Renal Insufficiency, Chronic; Sulfonamides; Sulfonic Acids; Uremia | 2014 |